TGF-β超家族細胞因子激活素A可驅動致病性Th17細胞分化
作者:
小柯機器人發布時間:2021/1/12 11:18:06
美國北卡羅萊納大學教堂山分校Yisong Y. Wan研究團隊發現,TGF-β超家族細胞因子激活素A在自身免疫性神經炎症過程中被誘導並驅動致病性Th17細胞分化。相關論文於2021年1月8日在線發表在《免疫》雜誌上。
研究人員探索了激活素A(與TGF-β1密切相關的TGF-β超家族成員)在T17病原細胞分化中的T細胞內在作用。在患有復發緩解型多發性硬化的個體和患有實驗性自身免疫性腦脊髓炎的小鼠中,激活素A的表達發生增加。白介素6和激活素A的刺激誘導了一個分子程序,該程序反映了致病性Th17細胞的程序,並被阻斷了激活素A信號傳導所抑制。T細胞中激活素A及其受體ALK4的遺傳破壞在體外和體內損害致病性Th17細胞分化。
從機制上講,TGF-β1-ALK5抑制了對病原Th17細胞分化至關重要的細胞外信號調節激酶(ERK)磷酸化,但激活素-A-ALK4信號卻沒有抑制。因此,激活素A驅動致病性Th17細胞分化,這暗示了激活素A-ALK4-ERK信號軸是Th17細胞相關疾病的治療靶標。
據了解,Th17細胞具有致病性和非致病性功能。儘管細胞因子TGF-β1有助於Th17細胞分化,但對於生成致病性Th17細胞卻是必不可少的。
附:英文原文
Title: The TGF-β superfamily cytokine Activin-A is induced during autoimmune neuroinflammation and drives pathogenic Th17 cell differentiation
Author: Bing Wu, Song Zhang, Zengli Guo, Yanmin Bi, Mingxia Zhou, Ping Li, Maryamsadat Seyedsadr, Xiaojiang Xu, Jian-liang Li, Silva Markovic-Plese, Yisong Y. Wan
Issue&Volume: 2021-01-08
Abstract: Th17 cells are known to exert pathogenic and non-pathogenic functions. Although thecytokine transforming growth factor β1 (TGF-β1) is instrumental for Th17 cell differentiation,it is dispensable for generation of pathogenic Th17 cells. Here, we examined the T cell-intrinsicrole of Activin-A, a TGF-β superfamily member closely related to TGF-β1, in pathogenicTh17 cell differentiation. Activin-A expression was increased in individuals withrelapsing-remitting multiple sclerosis and in mice with experimental autoimmune encephalomyelitis.Stimulation with interleukin-6 and Activin-A induced a molecular program that mirroredthat of pathogenic Th17 cells and was inhibited by blocking Activin-A signaling. Geneticdisruption of Activin-A and its receptor ALK4 in T cells impaired pathogenic Th17cell differentiation in vitro and in vivo. Mechanistically, extracellular-signal-regulated kinase (ERK) phosphorylation, whichwas essential for pathogenic Th17 cell differentiation, was suppressed by TGF-β1-ALK5but not Activin-A-ALK4 signaling. Thus, Activin-A drives pathogenic Th17 cell differentiation,implicating the Activin-A-ALK4-ERK axis as a therapeutic target for Th17 cell-relateddiseases.
DOI: 10.1016/j.immuni.2020.12.010
Source: https://www.cell.com/immunity/fulltext/S1074-7613(20)30538-0